Cargando…
Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency
Corneal failure is a highly prevalent cause of blindness. One special cause of corneal failure occurs due to malfunction or destruction of the limbal stem cell niche, upon which the superficial cornea depends for homeostatic maintenance and wound healing. Failure of the limbal niche is referred to a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466237/ https://www.ncbi.nlm.nih.gov/pubmed/34575560 http://dx.doi.org/10.3390/pharmaceutics13091483 |
_version_ | 1784573084444917760 |
---|---|
author | Calonge, Margarita Nieto-Miguel, Teresa de la Mata, Ana Galindo, Sara Herreras, José M. López-Paniagua, Marina |
author_facet | Calonge, Margarita Nieto-Miguel, Teresa de la Mata, Ana Galindo, Sara Herreras, José M. López-Paniagua, Marina |
author_sort | Calonge, Margarita |
collection | PubMed |
description | Corneal failure is a highly prevalent cause of blindness. One special cause of corneal failure occurs due to malfunction or destruction of the limbal stem cell niche, upon which the superficial cornea depends for homeostatic maintenance and wound healing. Failure of the limbal niche is referred to as limbal stem cell deficiency. As the corneal epithelial stem cell niche is easily accessible, limbal stem cell-based therapy and regenerative medicine applied to the ocular surface are among the most highly advanced forms of this novel approach to disease therapy. However, the challenges are still great, including the development of cell-based products and understanding how they work in the patient’s eye. Advances are being made at the molecular, cellular, and tissue levels to alter disease processes and to reduce or eliminate blindness. Efforts must be coordinated from the most basic research to the most clinically oriented projects so that cell-based therapies can become an integrated part of the therapeutic armamentarium to fight corneal blindness. We undoubtedly are progressing along the right path because cell-based therapy for eye diseases is one of the most successful examples of global regenerative medicine. |
format | Online Article Text |
id | pubmed-8466237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84662372021-09-27 Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency Calonge, Margarita Nieto-Miguel, Teresa de la Mata, Ana Galindo, Sara Herreras, José M. López-Paniagua, Marina Pharmaceutics Review Corneal failure is a highly prevalent cause of blindness. One special cause of corneal failure occurs due to malfunction or destruction of the limbal stem cell niche, upon which the superficial cornea depends for homeostatic maintenance and wound healing. Failure of the limbal niche is referred to as limbal stem cell deficiency. As the corneal epithelial stem cell niche is easily accessible, limbal stem cell-based therapy and regenerative medicine applied to the ocular surface are among the most highly advanced forms of this novel approach to disease therapy. However, the challenges are still great, including the development of cell-based products and understanding how they work in the patient’s eye. Advances are being made at the molecular, cellular, and tissue levels to alter disease processes and to reduce or eliminate blindness. Efforts must be coordinated from the most basic research to the most clinically oriented projects so that cell-based therapies can become an integrated part of the therapeutic armamentarium to fight corneal blindness. We undoubtedly are progressing along the right path because cell-based therapy for eye diseases is one of the most successful examples of global regenerative medicine. MDPI 2021-09-16 /pmc/articles/PMC8466237/ /pubmed/34575560 http://dx.doi.org/10.3390/pharmaceutics13091483 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Calonge, Margarita Nieto-Miguel, Teresa de la Mata, Ana Galindo, Sara Herreras, José M. López-Paniagua, Marina Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency |
title | Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency |
title_full | Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency |
title_fullStr | Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency |
title_full_unstemmed | Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency |
title_short | Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency |
title_sort | goals and challenges of stem cell-based therapy for corneal blindness due to limbal deficiency |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466237/ https://www.ncbi.nlm.nih.gov/pubmed/34575560 http://dx.doi.org/10.3390/pharmaceutics13091483 |
work_keys_str_mv | AT calongemargarita goalsandchallengesofstemcellbasedtherapyforcornealblindnessduetolimbaldeficiency AT nietomiguelteresa goalsandchallengesofstemcellbasedtherapyforcornealblindnessduetolimbaldeficiency AT delamataana goalsandchallengesofstemcellbasedtherapyforcornealblindnessduetolimbaldeficiency AT galindosara goalsandchallengesofstemcellbasedtherapyforcornealblindnessduetolimbaldeficiency AT herrerasjosem goalsandchallengesofstemcellbasedtherapyforcornealblindnessduetolimbaldeficiency AT lopezpaniaguamarina goalsandchallengesofstemcellbasedtherapyforcornealblindnessduetolimbaldeficiency |